Potassium-competitive acid blocker versus proton pump inhibitor for the healing effect of gastric ulcer induced by endoscopic submucosal dissectio
Not Applicable
- Conditions
- early gastric cancer
- Registration Number
- JPRN-UMIN000022006
- Lead Sponsor
- Sado general hospital
- Brief Summary
Our study indicated that lansoprazole was cost-effective and potent enough for the management of ESD ulcers, although vonoprazan is also sufficient.
- Detailed Description
Not available
Recruitment & Eligibility
- Status
- Complete: follow-up complete
- Sex
- All
- Target Recruitment
- 30
Inclusion Criteria
Not provided
Exclusion Criteria
Those who needed any additional anticancer therapy (surgery and/or chemotherapy) after ESD were excluded.
Study & Design
- Study Type
- Interventional
- Study Design
- Not specified
- Primary Outcome Measures
Name Time Method The primary endpoint was to evaluate the shrinking rate of ESD-induced ulcers between vonoprazan (20mg/day) group and lansoprazole (30mg/day) group 28 days after ESD.
- Secondary Outcome Measures
Name Time Method The secondary endpoint was to compare the preventive effect of vonoprazan and lansoprazole for delayed bleeding